srne-8ka_20150514.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K/A

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2015

 

SORRENTO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

001-36150

 

33-0344842

(State or other jurisdiction

 

(Commission File Number)

 

IRS Employer

of incorporation or organization)

 

 

 

Identification No.)

 

9380 Judicial Drive

San Diego, CA 92121

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (858) 210-3700

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4©)

 

 

 

 

 


 


 

 

EXPLANATORY NOTE

 

 

On May 15, 2015, Sorrento Therapeutics, Inc. (“Sorrento”) filed a Current Report on Form 8-K under Item 1.01 (the “Initial Report”) to report the sale to NantPharma, LLC of all of the Company’s equity interests in IgDraSol, Inc. (the “Transaction”).  This Current Report on Form 8-K/A amends Items 9.01(b) of the Initial Report to provide pro forma financial information related to the Transaction.  Except as stated in this Explanatory Note, no other information contained in the Initial Report is changed.

 

Item 9.01 Financial Statements and Exhibits.

 

(b) Pro Forma Financial Information.

Unaudited pro forma condensed consolidated financial information is filed as Exhibit 99.3 to this Current Report.

(d)Exhibits

Exhibit No.

Description

99.3

Unaudited Pro Forma Condensed Consolidated Financial Information.

 


 


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 5, 2016

 

 

 

 

SORRENTO THERAPEUTICS, INC.

 

 

 

 

 

By:

/s/ Henry Ji

 

 

Name:  Henry Ji

 

 

Title:    President and Chief Executive Officer